LIR Life Sciences Corp.
BBCMF
$0.20
$0.000.00%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 717.07% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 737.46% | -- | -- | -- | |
| Operating Income | -737.46% | -- | -- | -- | |
| Income Before Tax | -851.66% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -851.66% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -851.66% | -- | -- | -- | |
| EBIT | -737.46% | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 91.87% | -- | -- | -- | |
| Normalized Basic EPS | 91.96% | -- | -- | -- | |
| EPS Diluted | 91.87% | -- | -- | -- | |
| Normalized Diluted EPS | 91.96% | -- | -- | -- | |
| Average Basic Shares Outstanding | 331.53% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 331.53% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |